Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.
Chappidi MR, Iravani A, Stambler N, Baskaran S, DiPippo VA, Denes BS, Lin DW. Chappidi MR, et al. Among authors: iravani a. Clin Genitourin Cancer. 2024 Dec;22(6):102223. doi: 10.1016/j.clgc.2024.102223. Epub 2024 Sep 13. Clin Genitourin Cancer. 2024. PMID: 39357459
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Among authors: iravani a. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
Hofman MS, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Iravani A, Williams S, O'Brien J, Lawrentschuk N, Murphy DG. Hofman MS, et al. Among authors: iravani a. Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00251-7. doi: 10.1016/j.euo.2024.11.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39613566 Free article.
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.
Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, Yezefski TA, Haffner MC, Hawley JE, Montgomery RB, Yu EY, Schweizer MT, Chen DL, Iravani A. Demirci RA, et al. Among authors: iravani a. J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167. Online ahead of print. J Nucl Med. 2024. PMID: 39542703
A deep learning anthropomorphic model observer for a detection task in PET.
Shao M, Byrd DW, Mitra J, Behnia F, Lee JH, Iravani A, Sadic M, Chen DL, Wollenweber SD, Abbey CK, Kinahan PE, Ahn S. Shao M, et al. Among authors: iravani a. Med Phys. 2024 Oct;51(10):7093-7107. doi: 10.1002/mp.17303. Epub 2024 Jul 15. Med Phys. 2024. PMID: 39008812
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. Among authors: iravani a. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.
Gafita A, Martin AJ, Emmett L, Eiber M, Iravani A, Fendler WP, Buteau J, Sandhu S, Azad AA, Herrmann K, Stockler MR, Davis ID, Hofman MS. Gafita A, et al. Among authors: iravani a. Eur Urol Oncol. 2024 Apr 6:S2588-9311(24)00085-3. doi: 10.1016/j.euo.2024.03.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38584037
159 results